Mark Feitelson

Mark Feitelson's Title

Mark Feitelson holds the title of Chief Scientific Officer (CSO) and is a Co-Founder of his company. As CSO, Feitelson is responsible for overseeing the scientific and research direction of the company, ensuring that their projects are aligned with the company's strategic goals. His role also involves leading clinical trials, managing the R&D team, and maintaining high standards of scientific integrity and innovation. These responsibilities highlight his pivotal role in the company's advancements in medical research, particularly concerning psoriasis treatment.

Mark Feitelson's Article

Mark Feitelson has contributed to the scientific community with his published article titled 'Short-chain fatty acids in cancer pathogenesis'. This publication explores the role of short-chain fatty acids (SCFAs) in the development and progression of cancer, providing valuable insights into their potential therapeutic applications. Feitelson's work in this area underscores his expertise in both oncology and biochemistry, and his ability to contribute significant findings to the field. This article not only enhances his reputation as a researcher but also positions him as a thought leader in the intersection of metabolic pathways and cancer.

Mark Feitelson's Clinical Trial Results

Mark Feitelson recently announced positive results from the SFA-002 Phase 1b cohort 1 clinical trial for psoriasis. The trial, which focuses on mild-to-moderate chronic plaque psoriasis, demonstrated that SFA-002 could be a disease-modifying treatment with durable responses and an excellent safety profile. Notably, no related adverse events or toxicities were observed during the treatment period and follow-up. These promising results indicate that SFA-002 acts on multiple therapeutic pathways and provides an immunomodulatory effect by down-regulating levels of pro-inflammatory cytokines involved in psoriasis pathogenesis. The second cohort of the trial is ongoing, with a readout expected by the end of 2023.

Mark Feitelson's SFA-002 Drug Potential

SFA-002, a drug developed under the guidance of Mark Feitelson, holds significant promise in the treatment of psoriasis. According to Dr. Daniel Sauder, SFA-002 is an incredibly safe oral drug with very high efficacy. It has the potential to become a cornerstone treatment for psoriasis due to its ability to act on multiple therapeutic pathways and provide an immunomodulatory effect. The drug's favorable safety profile, combined with its effectiveness in down-regulating pro-inflammatory cytokines, positions it as a potentially transformative option for patients with psoriasis. The ongoing clinical trials will further elucidate its long-term benefits and impact on the disease.